Active substance
Doxycycline
- SFDA 16
- US FDA 151
- Health Canada 18
- US price lines 20
- NHS prices 5
- WHO EML 2
- Safety 20
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| APO-DOXY 100MG CAPS | 100 mg | Capsule · Oral use | 10 Blister | SAR 28.85 | Generic · Prescription | APOTEX | Valid |
| DOXYCIN | 100 mg | Capsule · Oral use | 10 Blister | SAR 21.65 | Generic · Prescription | RIYADH PHARMA | Valid |
| DOXYDAR | 100 mg | Capsule · Oral use | 10 Blister | SAR 12.10 | Generic · Prescription | DAR ALDAWA | Valid |
| DURADOX 100 MG CAPS | 100 mg | Capsule, hard · Oral use | 10 Blister | SAR 25.95 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Doxydar | 100 mg | Capsule, hard · Oral use | 500 Blister | SAR 412.80 | Generic · Prescription | DAR Al DAWA | Valid |
| Doxydar | 100 mg | Capsule · Oral use | 20 Blister | SAR 24.20 | Generic · Prescription | DAR ALDAWA | Valid |
| TABOCINE 100 | 100 mg | Capsule, hard · Oral use | 10 Blister | SAR 28.85 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Valid |
| VIBRAMYCIN 100MG TABLET | 100 mg | Tablet · Oral use | 10 Blister | SAR 29.80 | Generic · Prescription | PFIZER | Valid |
| DORYX CAPS 100MG | 100 mg | Capsule · Oral use | 7 Blister | SAR 18.15 | Generic · Prescription | F.H. FAULDING | Withdrawn by MAH · Not Marketed |
| DUMOXIN SYRUP 10MG-ML | 10 mg/ml | Syrup · Oral use | 1 Bottle | SAR 25.45 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| DUMOXIN TAB 100 MG | 100 mg | Tablet · Oral use | 10 Blister | SAR 28.85 | NCE · Prescription | XELLIA PHARMACEUTICAL APS | Withdrawn by MAH · Not Marketed |
| NOVO-DOXYLIN 100MG CAPS | 100 mg | Capsule · Oral use | 10 Blister | SAR 14.35 | Generic · Prescription | NOVOPHARM | Withdrawn by MAH · Not Marketed |
| VIBRAMYCIN 100MG TABLET | 100 mg | Tablet · Oral use | 10 Blister | SAR 32.05 | Generic · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| VIBRAMYCIN CAP 100 MG. | 100 mg | Capsule · Oral use | 10 Blister | SAR 32.00 | Generic · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| VIBRAMYCIN CAP 100 MG. | 100 mg | Capsule · Oral use | 5 Blister | SAR 17.95 | Generic · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| VIBRAMYCIN SYRUP 10 MG-ML | 10 mg/ml | Syrup · Oral use | 1 Bottle | SAR 14.65 | Generic · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BACTERIAL PROSTATITIS; ACUTE COUGH; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - IMPETIGO AND ECTHYMA; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - PURULENT SKIN AND SOFT TISSUE INFECTIONS (CUTANEOUS ABSCESSES, FURUNCLES, CARBUNCLES); BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - VIBRIO CHOLERAE; BRUCELLOSIS; COMMUNITY ACQUIRED PNEUMONEA; ENDOCARDITIS; ERYTHEMA; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; LICHEN PLANUS; MALARIA-PREVENTION AND CHEMOPROPHYLAXIS; MARGINAL ZONE LYMPHOMA; MUCOPURULENT CONJUCTIVITIS - CHLAMYDIAL CONJUNCTIVITIS; MYCOPLASMA GENITALIUM; NECROTIZING PERIODONTITIS AND NECROTIZING ULCERATIVE GINGIVITIS; OCULAR ROSACEA; ORCHITIS AND EPIDIDYMITIS; OSTEOMYELITIS; PAPULOPUSTULAR ROSACEA; PELVIC INFLAMMATORY DISEASE; PEMPHIGOID; PHYMATOUS ROSACEA (MILD TO MODERATE); Pyogenic Arthritis; SINUSITIS; TRAVEL RELATED INFECTIONS-TREATMENT; URETHRITIS & NONGONOCOCCAL URETHRIIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DOXYCYCLINE HYCLATE | EQ 50MG BASE; EQ 100MG BASE | capsule · oral | STRIDES PHARMA | Prescription | 29 Mar 1982 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE; EQ 50MG BASE | capsule · oral | ACTAVIS LABS FL INC | Prescription | 13 Oct 1982 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE; EQ 50MG BASE | tablet · oral | EPIC PHARMA LLC | Prescription | 8 Nov 1982 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE | tablet · oral | ACTAVIS LABS FL INC | Prescription | 2 Feb 1983 |
| DOXY 100 | EQ 100MG BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 9 Dec 1983 |
| DOXY 200 | EQ 200MG BASE/VIAL | injectable · injection | FRESENIUS KABI USA | Prescription | 9 Dec 1983 |
| DOXYCYCLINE HYCLATE | EQ 50MG BASE; EQ 100MG BASE | capsule · oral | CHARTWELL | Prescription | 11 Sep 1984 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE; EQ 50MG BASE | tablet · oral | CHARTWELL | Prescription | 11 Sep 1984 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE; EQ 50MG BASE | capsule · oral | HIKMA INTL PHARMS | Prescription | 7 Nov 1984 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE; EQ 50MG BASE | tablet · oral | STRIDES PHARMA INTL | Prescription | 7 Apr 1986 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE; EQ 50MG BASE | capsule · oral | SUN PHARM INDUSTRIES | Prescription | 10 Jul 1986 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 10 Jul 1986 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE/VIAL; EQ 200MG BASE/VIAL | injectable · injection | WEST-WARD PHARMS INT | Prescription | 16 Feb 1989 |
| MONODOX | EQ 100MG BASE; EQ 50MG BASE; EQ 75MG BASE; EQ 150MG BASE | capsule · oral | CHARTWELL RX | Prescription | 29 Dec 1989 |
| DOXYCYCLINE | EQ 50MG BASE; EQ 100MG BASE; EQ 75MG BASE | capsule · oral | SUN PHARM INDS LTD | Prescription | 22 Nov 2000 |
| DOXYCYCLINE | EQ 50MG BASE; EQ 100MG BASE; EQ 150MG BASE | capsule · oral | STRIDES PHARMA INTL | Prescription | 1 Dec 2000 |
| DOXYCYCLINE | EQ 50MG BASE; EQ 100MG BASE; EQ 75MG BASE; EQ 150MG BASE | tablet · oral | STRIDES PHARMA INTL | Prescription | 15 Dec 2000 |
| DOXYCYCLINE HYCLATE | EQ 100MG BASE | tablet · oral | HIKMA INTL PHARMS | Prescription | 2 Jul 2003 |
| DORYX MPC | EQ 60MG BASE | tablet, delayed release · oral | MAYNE PHARMA | Prescription | 6 May 2005 |
| DOXYCYCLINE HYCLATE | EQ 20MG BASE | tablet · oral | SUN PHARM INDUSTRIES | Prescription | 13 May 2005 |
| DOXYCYCLINE HYCLATE | EQ 20MG BASE | tablet · oral | EPIC PHARMA LLC | Prescription | 13 May 2005 |
| DOXYCYCLINE HYCLATE | EQ 20MG BASE | tablet · oral | CHARTWELL MOLECULAR | Prescription | 10 Nov 2005 |
| DOXYCYCLINE | EQ 50MG BASE; EQ 100MG BASE; EQ 75MG BASE; EQ 150MG BASE | tablet · oral | LANNETT CO INC | Prescription | 8 Dec 2005 |
| DOXYCYCLINE HYCLATE | EQ 20MG BASE | tablet · oral | PHARMOBEDIENT | Prescription | 28 Feb 2006 |
| ORACEA | 40MG | capsule · oral | GALDERMA LABS LP | Prescription | 26 May 2006 |
126 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-DOXYCYCLINE | 02556928 | 100 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-DOXY | 00740713 | 100 MG | CAPSULE · ORAL | APOTEX INC |
| APO-DOXY-TABS | 00874256 | 100 MG | TABLET · ORAL | APOTEX INC |
| APO-DOXYCYCLINE MR | 02512645 | 40 MG | CAPSULE (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | APOTEX INC |
| APPRILON | 02375885 | 40 MG | CAPSULE (IMMEDIATE- AND DELAYED-RELEASE) · ORAL | GALDERMA CANADA INC. |
| BIO-DOXYCYCLINE | 02561115 | 100 MG | TABLET · ORAL | BIOMED PHARMA |
| DOXYCIN TAB 100MG | 00860751 | 100 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
| DOXYCYCLINE FOR INJECTION USP | 02561441 | 100 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| DOXYTAB | 00887064 | 100 MG | TABLET · ORAL | PRO DOC LIMITEE |
| JAMP DOXYCYCLINE | 02528568 | 20 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP DOXYCYCLINE CAPSULES | 02528940 | 100 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP DOXYCYCLINE TABLETS | 02554372 | 100 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| M-DOXYCYCLINE | 02543478 | 100 MG | TABLET · ORAL | MANTRA PHARMA INC |
| NRA-DOXYCYCLINE | 02558505 | 100 MG | TABLET · ORAL | NORA PHARMA INC |
| PMS-DOXYCYCLINE | 02247104 | 20 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
| PRZ-DOXYCYCLINE | 02536250 | 100 MG | TABLET · ORAL | PHARMARIS CANADA INC |
| TEVA-DOXYCYCLINE | 00725250 | 100 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| TEVA-DOXYCYCLINE | 02158574 | 100 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DORYX MPC DR 60 MG TABLET | $18.1822 | per EA | 17 Dec 2025 |
| US NADAC | DOXYCYCLINE 25 MG/5 ML SUSP | $0.23041 | per ML | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE 50 MG TABLET | $4.69979 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYC DR 100 MG TAB | $2.18358 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYC DR 200 MG TAB | $5.17223 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYC DR 50 MG TAB | $1.56942 | per EA | 22 Apr 2026 |
| US NADAC | DOXYCYCLINE HYCLATE 100 MG CAP | $0.1049 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYCLATE 100 MG TAB | $0.11799 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYCLATE 150 MG TAB | $0.72427 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYCLATE 20 MG TAB | $0.09837 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYCLATE 50 MG CAP | $0.14441 | per EA | 23 Sep 2026 |
| US NADAC | DOXYCYCLINE HYCLATE 75 MG TAB | $0.54817 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Doxycycline 100mg capsules | £0.74 | 8 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Doxycycline 100mg dispersible tablets sugar free | £4.91 | 8 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Doxycycline 20mg tablets | £17.30 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Doxycycline 40mg modified-release capsules | £7.99 | 14 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Doxycycline 50mg capsules | £1.30 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.1. Access group antibiotics · core
First choice: Cholera; First choice: Chlamydia trachomatis; Second choice: Bacterial pneumonia (Community-acquired pneumonia - mild to moderate); Second choice: Cholera [children]; Second choice: Chronic obstructive pulmonary disease with acute exacerbation
Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate) (EMLc); 50 mg per 5 mL (calcium) (EMLc) | Parenteral > General injections > unspecified: 100 mg in vial powder for injection | Oral > Solid > dispersible tablet: 100 mg (as monohydrate) (EMLc) | Oral > Solid > dosage form: 50 mg (as hyclate) (EMLc); 100 mg (as hyclate) | Oral > Solid > dosage form: 100 mg (as hyclate) - 6.5.3.3. Antimalarial medicines > Medicines for chemoprophylaxis in travellers · core
Malaria due to Plasmodium falciparum
Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid | Oral > Solid > dispersible tablet: 100 mg (as monohydrate) | Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)
Safety signals and safety-related labeling changes
- US FDA 8 Aug 2025 VIBRA-TABS — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 8 Aug 2025 VIBRAMYCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 8 Aug 2025 VIBRAMYCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 8 Aug 2025 VIBRAMYCIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations - US FDA 2 Apr 2025 ORACEA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 1 Apr 2025 PERIOSTAT — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 31 Mar 2025 DORYX — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2025 ACTICLATE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2025 ACTICLATE CAP — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2025 DORYX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 31 Mar 2025 DORYX MPC — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 31 Mar 2025 LYMEPAK — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 31 Mar 2025 MONODOX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - EMA PRAC 28 Nov 2024 PRAC signal: Suicidality
Action for MAH: update of the product information: No - EMA PRAC 11 Apr 2024 PRAC signal: Suicidality
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.